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In this opinion article, we intend to elaborate on thyroid mediation of isoflavone effects mainly on
the bone of aging males, which appears to have an important role but is still insufficiently analyzed
in the existing literature. Namely, the consequences of exposure to endocrine-disrupting chemicals
strongly depend on the timing of interaction and life stages of humans and animals, so we intended
to highlight the thyroid-related mechanism underlying the beneficial effect of isoflavones on aged
male bone.
Isoflavones are plant polyphenolic compounds dominantly present in legumes. Soybean
products are the main source of isoflavones in the human diet, either consumed as food or as
isolated soy protein, extracts, supplements, or purified compounds (1). In plants, isoflavones are
mainly present as 7-O-β-D-glucosides (genistin and daidzin) and only in minor amounts in their
free form as aglycones (genistein and daidzein) (1). The aglycones are biologically a more potent
form, exerting hormone-like, antioxidant, anticarcinogenic, and osteoprotective actions (1). The
potential use of isoflavones in the prevention and treatment of osteoporosis is even more actual
considering that all current treatments manifest imperfections and bear the risks of side effects
after prolonged usage (2).
Several epidemiological studies and clinical trials have revealed that supplementation with soy
isoflavones improves bone health status in early and postmenopausal women (3). In parallel, aged
men may have more bone-related benefits from isoflavone application than women, especially in
the states of physiological or iatrogenic (prostate cancer therapy) androgen deficiency (4). Given
that the number of men above the age of 70 is continuously increasing, the problem of male
osteoporosis has been recognized as a major health-care challenge (5). Combined soy protein and
isoflavone supplementation in men with type 2 diabetes mellitus led to a significant reduction in
the bone resorption marker βCTX (6). However, epidemiological and clinical evidence regarding
the bone-protective role of isoflavones in men is still scarce. In the meantime, research data on the
mechanisms of action in well-defined models of male aging should provide useful insights into the
therapeutic possibilities of isoflavones.
Thyroid hormones are known to play an important role in the regulation of bone
metabolism, while isoflavones have been shown to interfere with thyroid homeostasis. Histological
analysis of the effects of human hypothyroidism revealed low bone turnover with decreased
osteoblast and osteoclast activities, resulting in increased mineralization without changes
in bone volume (7). Crucially, the excess of thyroid hormones in hyperthyroidism results
in stimulation of osteoclastogenesis and bone resorption (8). Gene expression of thyroid
receptor (TR) α1 and β1 is confirmed in osteoclasts, but there are still doubts whether
triiodothyronine (T3) stimulates osteoclast activity directly or whether these processes result
from T3 actions in osteoblasts, osteocytes, and/or other bone cells (9, 10). When it comes
to isoflavone effects in the context of thyroid status, in vitro and in vivo studies indicate
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different mechanisms of their action, whereas the changes of
circulating thyroid hormone levels represent the outcome of
all these effects. Namely, they inhibit thyroid peroxidase (TPO)
activity by acting as competitive substrates for iodination (11).
Genistein and daidzein inhibit binding of serum transport
protein transthyretin (TTR) to thyroid hormones (12).
However, the capacity of the thyroid system to compensate
the consequences of isoflavone actions depends on numerous
factors, such as insufficient iodine in the diet, co-exposure
with other goitrogens, and age and sex (13–15). Human
studies also indicate an association between increased risk of
developing goiter on the one hand and high intake of soy-
based foods combined with iodine deficiency on the other
(11). The TPO inhibition was confirmed by identification of
iodinated isoflavones in the urine of menopausal women upon
isoflavone supplementation (16). However, although some
clinical reports indicate the absence of the effect of isoflavones
on thyroid hormone status (17), isoflavones tripled the risk
of overt hypothyroidism development in postmenopausal
women with subclinical hypothyroidism (18). There are still
no available data regarding the potential remedial action of
isoflavones on the bones in hyperthyroid states. It might be of
importance for bone preservation, considering that both clinical
and experimental studies coherently indicate that reduced bone
density, osteoporosis, and increased fracture rate are associated
with hyperthyroidism (8).
In an orchidectomized rat model of the andropause (15–16
months old Wistar males), subcutaneous application of various
doses of genistein or daidzein (10 and 30 mg/kg b.m., daily for
3 weeks) suppressed thyroid activity, decreased thyroxin (T4)
and T3, and elevated thyroid-stimulating hormone (TSH) in
serum (19, 20). Such an effect of isoflavones was potentiated
by both androgen deprivation and age (21, 22). At the same
time, treatment of middle-aged rats with isoflavones (35 mg/kg
b.m., daily for 4 weeks) elevated expression of T3-responsive
genes, Dio1 enzyme activity, and concentration of T3 in the
liver by interfering with TTR, which resulted in a mixed
phenotype of systemic hypothyroidism and local (hepatic) tissue
hyperthyroidism (12, 14). To note, thyroxin-binding globulin
(TBG) is the major serum transport protein in humans but not
TTR, while isoflavones do not compete with thyroid hormones
for binding to TBG or albumin in vitro (12). However, TTR,
in comparison with TBG, seems to be responsible for much
of the immediate delivery of thyroid hormones to human
tissues (23). Endogenous sex steroids differently influence the
synthesis and stability of TBG in men and women (24). The
treatment of middle-aged females with isoflavones under the
same experimental setup remained without effects on thyroid
homeostasis (13), which is in coherence with the fact that
the females are less susceptible to perturbation of thyroid
homeostasis (25).
In our middle-aged orchidectomized model, genistein and
daidzein improved bone microarchitecture by increasing the
cancellous bone formation, trabecular thickness, and trabecular
number but decreasing the trabecular separation, all in the
proximal tibial metaphysis (20, 26). Marked reductions in
biochemical markers of bone formation, serum osteocalcin,
and urinary Ca2+ concentrations were observed in comparison
with those in orchidectomized controls (20, 26). In addition to
this, isoflavones beneficially affected Ca2+/PI balance through
modulation of parathyroid hormone/1.25(OH)2–vitamin
D3/calcitonin balance (27). Most experimental studies also
reported beneficial effects of soy isoflavones on the bone in
male models (28, 29). Similarly, genistein (10 mg/kg b.m.)
subcutaneously administered to ovariectomized females
exerted a beneficial, bone-sparing effect by increasing bone
mineral density and lowering serum osteocalcin concentration
(30). Moreover, daidzein may be more efficient than
genistein in the remediation of ovariectomy-induced bone
loss (31).
Although the signs of systemic hypothyroidism coincided
with higher bioavailability of thyroid hormones to bones in
our model, TSH elevation was a favorable outcome within the
frame of pituitary-thyroid mediation of bone-related isoflavone
effects. TSH plays a direct role in the regulation of bone turnover
independently of thyroid hormones (32). Heterozygous Tshr+/−
mice have normal levels of thyroid hormones and TSH but
decreased bone density. Additionally, Tshr null mice have severe
osteoporosis, and supplementation with T4 could not restore
bone mass (32). Treatment of ovariectomized rats with low
doses of TSH (insufficient to alter serum T3, T4, or TSH) also
demonstrated that TSH independently prevented bone loss and
increased bone mass (33). Human studies in postmenopausal
women confirmed that subcutaneous injection of recombinant
human TSH exerts both anti-resorptive and anabolic
actions (34).
Besides general adrenocortical and thyroid functions
interconnection in the regulation of energy balance, the interplay
between glucocorticoids and hypothalamic-pituitary-thyroid
axis may reflect adversely on morphofunctional characteristics
of bone tissue. Stress conditions and glucocorticoids per se
had been long ago established as the osteoporosis-promoting
factors (35, 36). Moreover, glucocorticoids decrease thyrotropin-
releasing hormone (TRH) gene expression in the hypothalamic
paraventricular nucleus (PVN), as well as TSH serum
concentrations in both rats and humans (37, 38). Given the
previous elaboration of beneficial effects of high TSH on the
bone (39), glucocorticoid indirect input (by lowering TSH)
may also provoke the adverse effect on the bone homeostasis.
Figure 1 provides a summary of data regarding thyroid
mediation and other relevant endocrine aspects of isoflavone
effects on osteoporotic bone in aged males. Genistein and
daidzein were reported to be the strong inhibitors of 3β-HSD
and cytochrome P450 21-hydroxylase enzymes, involved in
the process of corticosteroid oogenesis (40). In our rat model,
genistein and daidzein reduced both circulating levels of
ACTH and corticosterone, thus reducing the risk of circulating
glucocorticoid “pressure” on the osteoporotic bone (20, 26, 41).
Thus, the isoflavone-glucocorticoid-TSH triad provides an
additional favorable outcome in the context of pituitary-thyroid
mediation of bone-sparing effects.
Aside from the systemic effects of isoflavones, it is noteworthy
to observe the possibility of their interference with bioavailability
and signaling of thyroid hormones within the bone tissue.
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FIGURE 1 | Thyroid mediation and other relevant endocrine aspects of isoflavone effects on osteoporotic bone in aged males. TPO, thyroid peroxidase; TH, thyroid
hormone; TSH, thyroid-stimulating hormone; TTR, transthyretin; TR, thyroid receptor; MCT8, monocarboxylate transporter-8; PTH, parathormone; CT, calcitonin; vit.
D, vitamin D. Arrows with “+” mean bone-protective effect; arrows with “–” mean bone-deteriorating effect; arrows with “#” mean local tissue changes upon androgen
deprivation within the thyroid endocrine system.
Genistein and daidzein may enhance T3-liganded, TR α
and β-mediated transcription in a concentration-dependent
manner (42). Moreover, although the role of thyroid hormone
transporters in bone is still uncertain, the expression of
monocarboxylate transporter-8 (MCT8) and L-amino acid
transporter (LAT)-1 and LAT-2 was confirmed in osteoblasts
and osteoclasts at all stages of cell differentiation (43). In
parallel, it was suggested that genistein may bind to human
MCT8 protein (44). Apart from thyroid hormone (TH)
transporters, the relative activities of type 2 and 3 deiodinases
(Dio2 and Dio3) determine intracellular availability of T3
in the bone, whereas Dio1 is not expressed in the skeleton
(43). Genistein was shown to be a Dio1-specific inhibitor,
without affecting the activity of Dio2 and Dio3 in vitro (45).
The relevance of direct putative mechanisms of isoflavone
action that might influence local tissue bioavailability and
thyroid hormone signaling in bone still awaits further in
vivo analyses.
In addition to the endocrine interference, the direct effect
of isoflavones on the osteogenesis and osteoclastogenesis is
also described, whereas selective estrogen receptor binding
(46) represents one of the most suspected mechanisms. These
compounds may also affect the paracrine activity in the bone,
calcium channel signaling, and expression of osteoblastogenesis
modulator core-binding factor 1 or receptor activator of nuclear
factor-κB (RANK) expressed by osteoclasts, together with RANK
ligand (RANKL) and osteoprotegerin (OPG) produced by
osteoblasts (47).
The biopotency of aglycones is highly questioned at the
moment because of their rapid metabolism, low serum
concentration, and bioavailability upon supplementation
(48). However, phase II of polyphenols conjugation does
not always decrease their biological activity for a number of
physiological endpoints (48). Certain isoflavone conjugates
may represent an intracellular pool for generation and
release of aglycones (49). Interestingly, the concentration
of genistein in the thyroid and mammary gland tissue was
reported to be markedly higher than in rat circulation (48).
Apart from circulation, data regarding the concentration of
isoflavones and their metabolites in bone tissue are still lacking,
as well as the information regarding their potential bone-
sparing effects, except for highly potent (S)-equol produced
from daidzein by the gut microbiota. Great variations in
response to pharmacotherapeutics, including isoflavones,
point to a personalized approach. Definition of isoflavone
metabolizing phenotypes as a strategy for identification
of individuals might benefit from osteoporosis-preventive
strategies using isoflavones.
CONCLUSION
This opinion article is founded on the fact that soy isoflavones
represent effective bioactive compounds that interfere with
thyroid cascade and signaling at various points in a sex-and-age-
dependent manner. A deeper understanding of the mechanisms
involved in thyroid-mediated isoflavone action in the bone is
even more important considering the complexity of regulation
of bone remodeling, as well as the actuality of the bone
disorders in advanced age. Potentially, therapeutic exploitation
of biomedical essence presented here may inspire further
research and development of isoflavone-based supplementation
for men suffering from endocrine disorders and secondary
osteoporosis. Basic and clinical research about isoflavone effects
in thyrotoxicosis and associated bone pathology could be of
particular interest.
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